scholarly journals Pembrolizumab (Keytruda)

2021 ◽  
Vol 1 (12) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Esophagogastric Junction ◽  
Performance Status ◽  
Growth Factor Receptor ◽  
Previous Treatment ◽  
Cost Effective ◽  
Epidermal Growth ◽  
Public Drug

CADTH recommends that Keytruda should be reimbursed by public drug plans for the treatment of esophageal or human epidermal growth factor receptor 2 (HER2)-negative esophagogastric junction (EGJ) cancer that cannot be removed by surgery or is metastatic, if certain conditions are met. Keytruda should only be covered to treat adult patients who have not received previous treatment for advanced or metastatic esophageal or EGJ cancer and who have good performance status. Keytruda should only be reimbursed if prescribed in combination with platinum and fluoropyrimidine–based chemotherapy and given by a clinician who is experienced in treating cancer. The price of Keytruda must be lowered to be cost-effective and affordable.

scholarly journals Epidermal growth factor receptor protein expression in lung cancer and survival analysis

2018 ◽  
Vol 5 (3) ◽  
pp. 550
Author(s):  
Shivalingaswamy Salimath ◽  
Jayaraj B. S. ◽  
Mahesh P. A. ◽  
M. D. Majeed Pasha ◽  
Lokesh K. S. ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Multivariate Analysis ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Performance Status ◽  
Growth Factor Receptor ◽  
Egfr Expression ◽  
Epidermal Growth ◽  
Nsclc Patients

Background: Epidermal Growth Factor Receptor (EGFR) is one of the important molecules involved in lung cancer initiation and progression. Studies on over expression of EGFR and its survival in relation with Non-small cell lung cancer (NSCLC) patients have yielded controversial results. Prevalence of EGFR expression in NSCLC patients and 6-month survival in south Indian population is unknown.Methods: We carried out a prospective study in tertiary hospital. Diagnosed patients with NSCLC were included in the study and were interviewed with questionnaire containing demography and investigations like Chest X-ray, CT thorax, Bronchoscopy were recorded. EGFR expression analysis was done for all patients and were followed up monthly for 6 months and details of survival and treatment were collected. Cox regression analysis was used to assess their survival.Results: 50 patients with NSCLC were included. Forty-four (88%) were men, median age of study group was 65 years. Twenty-seven patients (54%) had Adenocarcinoma, 14 patients (28%) had Squamous cell carcinoma, 7 patients (14%) had poorly differentiated carcinoma and 2 patients (4%) had large cell carcinoma. Thirty-four (68%) samples were positive for EGFR expression. On multivariate analysis we found patients who took chemotherapy and with good performance status (Karnofsky score >65 and Eastern Cooperative Oncology Group >2.5) had better survival at 6 months.Conclusions: Patients with EGFR positivity had better survival with chemotherapy but worse with radiotherapy. Patients who took chemotherapy and had good performance status had better survival on multivariate analysis. We didn’t find any correlation between EGFR positivity and poor survival.

Pathological Complete Response after Preoperative Chemotherapy with a Regimen Containing Trastuzumab in Esophagogastric Junction Adenocarcinoma: A Case Report

2016 ◽  
Author(s):  
Keisuke Arai ◽  
Shingo Kanaji ◽  
Daiki Okamoto ◽  
Ritsuko Maehara ◽  
Masashi Yamamoto ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Preoperative Chemotherapy ◽  
Esophagogastric Junction ◽  
Pathological Complete Response ◽  
Growth Factor Receptor ◽  
Complete Response ◽  
Esophagogastric Junction Adenocarcinoma ◽  
Epidermal Growth

Abstract ABSTRACT Introduction Perioperative adjuvant treatment for esophagogastric junction adenocarcinoma has been attempted, but efficacy of preoperative therapy is unclear. We report here a case of pathological complete response after preoperative treatment containing trastuzumab in esophagogastric junction adenocarcinoma. Case presentation A 54-year-old man presented at our institute with dysphagia. Esophagogastroduodenoscopy and computed tomography revealed an 8 x 5 cm-sized tumor on the gastric cardia and lower intrathoracic esophagus with invasion to the diaphragm (T4bN0M0, StageIIIB). Biopsy showed a well-differentiated and human epidermal growth factor receptor 2-positive adenocarcinoma. He received 2 cycles of preoperative chemotherapy consisting of trastuzumab, cisplatin, and capecitabine without severe toxicity. Afterwards, he underwent esophagectomy and total gastrectomy with mediastinal and abdominal D2 lymph node dissections. No cancer cells were detected during histopathological examination, indicating pathological complete response. Conclusion Regimens containing trastuzumab are feasible and promising as preoperative chemotherapy for human epidermal growth factor receptor 2-positive esophagogastric junction adenocarcinoma.

scholarly journals Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas

Cancer ◽  
2007 ◽  
Vol 109 (4) ◽  
pp. 658-667 ◽  
Author(s):  
Kim L. Wang ◽  
Tsung-Teh Wu ◽  
In Seon Choi ◽  
Huamin Wang ◽  
Erika Resetkova ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Esophagogastric Junction ◽  
Growth Factor Receptor ◽  
Epidermal Growth

scholarly journals Clinicopathologic Characteristics and Treatment Outcomes of Patients With Up-Front Metastatic Breast Cancer: Single-Center Experience in India

2019 ◽  
pp. 1-9
Author(s):  
Ajay Gogia ◽  
Suryanarayana Vishnu S. Deo ◽  
Dayanand Sharma ◽  
Sanjay Thulkar ◽  
Rakesh Kumar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Metastatic Breast Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Triple Negative ◽  
Performance Status ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
Epidermal Growth

PURPOSE Approximately 5% to 10% of patients with breast cancer present with up-front metastasis and carry a poor prognosis (5-year survival rates of approximately 20%). To date, little is known about the long-term outcome of patients with metastatic breast cancer from developing nations. MATERIALS AND METHODS We performed an ambispective review of approximately 1,800 patients who were registered in breast cancer clinics between January 2012 and August 2018. Approximately 410 (22.8%) patients presented with up-front metastasis. Out of 410, 375 were considered for additional analysis. Clinical, pathologic, and radiologic details were obtained from the medical records. RESULTS Median age of presentation was 49 years (range, 22 to 80 years), and median duration of symptoms was 6 months (interquartile range, 3-12 months). Baseline receptor status suggested that 234 patients (62.4%) were hormone receptor (HR) positive, 145 (38.6%) were human epidermal growth factor receptor positive, and 69 (18.6%) had triple-negative breast cancer. Various sites of metastasis were: visceral 219 (58.4%), bone only 100 (26.7%), nonregional lymph node metastasis 21 (5.6%), brain 10 (2.7%), and others 25 (5.8%). Approximately 309 patients (82.4%) received up-front chemotherapy, 192 HR-positive patients (82.1%) received endocrine therapy, and 78 human epidermal growth factor receptor–positive patients (53.8%) received targeted agents. Median progression-free survival was 14.2 months (95% CI, 12.7 to 16.8 months), and median overall survival (OS) was 31.7 months (95% CI, 25.8 to 38.2 months) for the cohort. Median time of follow-up was 22.2 months. On multivariable Cox regression analysis, HR-positive disease, good performance status (0 or 1), and oligometastasis were associated with better OS, whereas triple-negative breast cancer and liver and brain metastasis were associated with inferior OS. CONCLUSION This is the first comprehensive study, to our knowledge, of metastatic breast cancer from India. HR-positive status, oligometastasis, and good performance status were associated with better outcomes.

Sign in / Sign up

Export Citation Format

Share Document